Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Ulcerative Colitis Acute
Interventions: Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Colitis, Ulcerative
Interventions: Placebo, COLAL-PRED; Drug
Lead sponsor: Prometheus Laboratories; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 89
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 78 more

Conditions: Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Interventions: Xylitol, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ulcerative Colitis, Left-sided Ulcerative Colitis, Distal Ulcerative Colitis
Interventions: Zoenasa-1:4, Mesalamine Enema; Drug
Lead sponsor: Altheus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 45
States / cities: Birmingham, Alabama • Dothan, Alabama • Lakewood, Colorado + 39 more

Conditions: Canker Sore
Interventions: Luminance RED Low Level Laser Therapy Device; Device
Lead sponsor: ProofPilot; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Partial Thickness Wound, Pressure Ulcer, Venous Ulcer, Diabetic Ulcer, Surgical Wounds, Trauma Wounds, Draining Wounds, Chronic Vascular Ulcer
Interventions: PuraPly™ Antimicrobial Wound Matrix; Device
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 15
States / cities: Prescott Valley, Arizona • Jupiter, Florida • Miami, Florida + 12 more

Conditions: Venous Leg Ulcers
Interventions: Aurix; Device
Lead sponsor: Cytomedix; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions: Urinary Bladder Matrix (UBM) sheet device for Venous Leg Ulcers, Urinary Bladder Matrix (UBM) sheet device for Diabetic Foot Ulcers, AmnioExcel Plus for Venous Leg Ulcers, AmnioExcel Plus for Diabetic Foot Ulcers, Standard of Care; Device · Procedure
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Vista, California + 9 more

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin; Drug
Lead sponsor: Cogentus Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 247
States / cities: Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more

Conditions: Spinal Cord Injuries, Pressure Injuries
Interventions: pulsed wound irrigation (PWI), electrical stimulation (ES), electrical stimulation (ES) and pulsed wound irrigation (PWI); Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Venous Leg Ulcer
Interventions: EpiFix, Compression Therapy; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Boca Raton, Florida • Framingham, Massachusetts • Tulsa, Oklahoma + 2 more

Conditions: Keratitis, Corneal Ulcer
Interventions: PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial Tears; Combination Product · Other
Lead sponsor: Peschke GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more

Conditions: Wound
Interventions: Standard of Care Treatment or Standard of Care Treatment plus Miro3D Wound Matrix; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Eustachian Tube Dysfunction, Middle Ear Barotrauma, Middle Ear Disease, Middle Ear; Injury, Pressure Injury, Ear Barotrauma
Interventions: Hyperbaric Compression Profile; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Sleepy Hollow, New York

Conditions: Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 61
States / cities: Lowell, Arkansas • Anaheim, California • Folsom, California + 56 more

Conditions: Ulcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis, Inflammatory Bowel Disease (IBD)
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: New Haven, Connecticut • Miami, Florida • Orlando, Florida + 8 more

Conditions: Diabetic Foot Infection, Diabetic Foot
Interventions: Topical Pravibismane, Standard of Care; Drug · Other
Lead sponsor: Microbion Corporation; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Fresno, California • Dallas, Texas • McAllen, Texas + 1 more

Conditions: Inflammation, Burns, Ulcers
Interventions: Mepilex Border Ag; Device
Lead sponsor: Molnlycke Health Care AB; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Momtgomery, Alabama • Iowa City, Iowa • The Bronx, New York

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more

Conditions: Diabetic Foot
Interventions: ON101 Cream, Aquacel® Hydrofiber® dressing; Drug · Other
Lead sponsor: Oneness Biotech Co., Ltd.; Industry
Eligibility: 20 Years to 80 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Fresno, California

Conditions: Diabetic Foot Ulcer
Interventions: gentamicin-collagen sponge and levofloxacin, Levofloxacin only; Drug
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Lakeland, Florida

Conditions: Esophagitis, Inflammation, Gastritis, Abdominal Pain, Heartburn
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Gastroesophageal Reflux
Interventions: Rabeprazole sodium; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Up to 44 Weeks
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 10
States / cities: Orange, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more

Conditions: Diabetes, Foot Ulcer
Interventions: Tailored Intervention (TI), Current Practice (CP); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

Luminance RED for Canker Sores

The RESPOND Registry

Effectiveness of Aurix Therapy in Venous Leg Ulcers

A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

Physical Therapy Wound Care Modalities in Patients With Spinal Cord Injury (SCI)

Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers

Miro3D Randomized Controlled Trial (RCT)

Effect of Total Compression Time and Rate (Slope) on Incidence of Symptomatic ETD and MEB: A Phase II Prospective Study.

Fecal Biomarker Study for Patients With Ulcerative Colitis

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

STEP UP to Avert Amputation in Diabetes